Login / Signup

Impact of performance status on overall survival in patients with relapsed and/or refractory multiple myeloma: Real-life outcomes of daratumumab treatment.

Garbriel AframCharlotte GranJohanna B BruchfeldArnika Kathleen WagnerAlamdar HussainEvren AliciHareth Nahi
Published in: European journal of haematology (2020)
Daratumumab remains an attractive treatment option, especially in patients with poor performance and increased frailty. Furthermore, our observations suggest that patients with ECOG 2 and 3 status require additional supportive and/or palliative therapies to compensate for a potentially effective but encompassing late-line therapy. In conclusion, further prospective studies are needed to elucidate the impact of ECOG 2 and 3 status in patients with RRMM.
Keyphrases